Charlene M T Robertson1, Man-Joe Watt, Yutaka Yasui. 1. Section of Neurosciences, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. charlene.robertson@capitalhealth.ca
Abstract
CONTEXT: Although cerebral palsy (CP) among extremely premature infants has been reported as a major morbidity outcome, there are difficulties comparing published CP rates from many sites over various birth years. OBJECTIVE: To assess the changes in population-based, gestational age-specific prevalence rates of CP among extremely premature infants over 30 years. DESIGN: Prospective population-based longitudinal outcome study. SETTING AND PARTICIPANTS: In Northern Alberta, 2318 infants 20 to 27 weeks' gestational age with birth weights of 500 to 1249 g were liveborn from 1974 through 2003. By 2 years of age, 1437 (62%) had died, 23 (1%) were lost to follow-up, and 858 (37%) had received multidisciplinary neurodevelopmental assessment. MAIN OUTCOME MEASURE: Population-based prevalence rates of CP were determined. Logistic regression with linear spline was used to assess changes in CP prevalence over time. RESULTS: At age 2 years, 122 (14.2%) of 858 survivors had CP. This diagnosis was confirmed for each child by age 3 years or older. Among those whose gestational age was 20 to 25 weeks, population-based survival increased from 4% to 31% (P<.001), while CP prevalence per 1000 live births increased monotonically from 0 to 110 until the years 1992-1994 (P<.001) and decreased thereafter to 22 in the years 2001-2003 (P<.001). Among those whose gestational age was 26 to 27 weeks, population-based survival increased from 23% to between 75% and 80% (P<.001), while CP prevalence per 1000 live births increased monotonically from 15 to 155 until the years 1992-1994 (P<.001) and then decreased to 16 in the years 2001-2003 (P<.001). For all survivors born in the years 2001-2003, CP prevalence was 19 per 1000 live births. CONCLUSION: Population-based CP prevalence rates for children whose gestational age was 20 to 27 weeks and whose birth weight ranged from 500 to 1249 g show steady reductions in the last decade with stable or reducing mortality, reversing trends prior to 1992-1994.
CONTEXT: Although cerebral palsy (CP) among extremely premature infants has been reported as a major morbidity outcome, there are difficulties comparing published CP rates from many sites over various birth years. OBJECTIVE: To assess the changes in population-based, gestational age-specific prevalence rates of CP among extremely premature infants over 30 years. DESIGN: Prospective population-based longitudinal outcome study. SETTING AND PARTICIPANTS: In Northern Alberta, 2318 infants 20 to 27 weeks' gestational age with birth weights of 500 to 1249 g were liveborn from 1974 through 2003. By 2 years of age, 1437 (62%) had died, 23 (1%) were lost to follow-up, and 858 (37%) had received multidisciplinary neurodevelopmental assessment. MAIN OUTCOME MEASURE: Population-based prevalence rates of CP were determined. Logistic regression with linear spline was used to assess changes in CP prevalence over time. RESULTS: At age 2 years, 122 (14.2%) of 858 survivors had CP. This diagnosis was confirmed for each child by age 3 years or older. Among those whose gestational age was 20 to 25 weeks, population-based survival increased from 4% to 31% (P<.001), while CP prevalence per 1000 live births increased monotonically from 0 to 110 until the years 1992-1994 (P<.001) and decreased thereafter to 22 in the years 2001-2003 (P<.001). Among those whose gestational age was 26 to 27 weeks, population-based survival increased from 23% to between 75% and 80% (P<.001), while CP prevalence per 1000 live births increased monotonically from 15 to 155 until the years 1992-1994 (P<.001) and then decreased to 16 in the years 2001-2003 (P<.001). For all survivors born in the years 2001-2003, CP prevalence was 19 per 1000 live births. CONCLUSION: Population-based CP prevalence rates for children whose gestational age was 20 to 27 weeks and whose birth weight ranged from 500 to 1249 g show steady reductions in the last decade with stable or reducing mortality, reversing trends prior to 1992-1994.
Authors: Paul P Drury; Joanne O Davidson; Lotte G van den Heuij; Sidhartha Tan; Richard B Silverman; Haitao Ji; Arlin B Blood; Mhoyra Fraser; Laura Bennet; Alistair Jan Gunn Journal: Exp Neurol Date: 2013-10-09 Impact factor: 5.330
Authors: Betty R Vohr; Bonnie E Stephens; Rosemary D Higgins; Carla M Bann; Susan R Hintz; Abhik Das; Jamie E Newman; Myriam Peralta-Carcelen; Kimberly Yolton; Anna M Dusick; Patricia W Evans; Ricki F Goldstein; Richard A Ehrenkranz; Athina Pappas; Ira Adams-Chapman; Deanne E Wilson-Costello; Charles R Bauer; Anna Bodnar; Roy J Heyne; Yvonne E Vaucher; Robert G Dillard; Michael J Acarregui; Elisabeth C McGowan; Gary J Myers; Janell Fuller Journal: J Pediatr Date: 2012-03-14 Impact factor: 4.406
Authors: Amanda E Graf; Krista M Haines; Christopher R Pierson; Brad N Bolon; Ronald H Houston; Markus Velten; Kathryn M Heyob; Lynette K Rogers Journal: Life Sci Date: 2013-11-28 Impact factor: 5.037
Authors: Karl C K Kuban; Elizabeth N Allred; Michael O'Shea; Nigel Paneth; Marcello Pagano; Alan Leviton Journal: J Pediatr Date: 2008-06-02 Impact factor: 4.406
Authors: Paul P Drury; Joanne O Davidson; Sam Mathai; Lotte G van den Heuij; Haitao Ji; Laura Bennet; Sidhartha Tan; Richard B Silverman; Alistair J Gunn Journal: Neuropharmacology Date: 2014-04-12 Impact factor: 5.250